Akcea has licensed one of its pipeline antisense drugs to Pfizer.
The drug, AKCEA-ANGPTL3-Lrx, is designed to reduce the production of a protein in the liver which is a key regulator of triglycerides, cholesterol, glucose and energy metabolism. The drug is currently being studied in a Phase 2 trial of people with type 2 diabetes, high triglycerides and nonalcoholic fatty liver disease and results are expected next year.
Pfizer has agreed to pay US$250m upfront to Akcea and Ionis, and there is the potential for the two companies to earn a further US$1.3 bn in payments on achievement of development, regulatory and sales milestones, as well as double-digit royalties.
Pfizer will assume responsibility for all future studies.
https://xconomy.com/boston/2019/10/...shakeup-dishes-heart-drug-to-pfizer-for-250m/
https://www.biopharmadive.com/news/akcea-pfizer-heart-disease-deal-rebound/564468/
Akcea has licensed one of its pipeline antisense drugs to...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.000(0.00%) |
Mkt cap ! $699.9M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 25000 | 1 |
View Market Depth
| Last trade - 09.11am 24/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |
Day chart unavailable